OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.820
+0.020 (1.11%)
Nov 6, 2025, 4:00 PM EST - Market closed
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$3,250,384
Market Cap
61.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OSTX News
- 15 days ago - OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 20 days ago - OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 27 days ago - OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 4 weeks ago - OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting - Newsfile Corp
- 4 weeks ago - OS Therapies to Participate in Fall 2025 Conferences and Events - Newsfile Corp
- 5 weeks ago - OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update - Newsfile Corp
- 6 weeks ago - OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT - Newsfile Corp
- 7 weeks ago - OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit - Newsfile Corp